To determine whether HOXA13 expression levels determine the clinical progression or outcome of glioma patients, we examined the overall survival rates of the high-grade glioma patients (samples from CGGA, REMBRANDT and GSE16011) and GBM patients (samples from TCGA) using Kaplan-Maier analysis and log-rank comparison. The gene discussed is HOXA13; the disease is central nervous system cancer.